106308-44-5
106308-44-5 structure
- Name: Rufinamide
- Chemical Name: Rufinamide
- CAS Number: 106308-44-5
- Molecular Formula: C10H8F2N4O
- Molecular Weight: 238.193
- Catalog: Biochemical Inhibitor Transmembrane Transporters Sodium Channel inhibitor
- Create Date: 2018-09-18 22:06:43
- Modify Date: 2024-01-01 20:15:47
-
Rufinamide(E 2080; CGP 33101; RUF 331) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).IC50 Value:Target: in vitro:in vivo: Rufinamide and amitriptyline alleviated injury-induced mechanical allodynia for 4 h (maximal effect: 0.10 ± 0.03 g (mean ± SD) to 1.99 ± 0.26 g for rufinamide and 0.25 ± 0.22 g to 1.92 ± 0.85 g for amitriptyline) in mice [1]. Oral rufinamide suppressed pentylenetetrazol-induced seizures in mice (ED(50) 45.8 mg/kg) but not rats, and was active against MES-induced tonic seizures in mice (ED(50) 23.9 mg/kg) and rats (ED(50) 6.1 mg/kg) [2]. Intraperitoneal rufinamide suppressed pentylenetetrazol-, bicuculline-, and picrotoxin-induced clonus in mice (ED(50) 54.0, 50.5, and 76.3 mg/kg, respectively).Clinical trial: Exploratory Study to Evaluate the Effect of SYN-111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD). Phase 2
| Name | Rufinamide |
|---|---|
| Synonyms |
1-[(2,6-difluorophenyl)methyl]-1H-1,2,3-Triazole-4-carboxamide
1-(2,6-Difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide Rufinamide 1H-1,2,3-Triazole-4-carboxamide, 1-[(2,6-difluorophenyl)methyl]- 1-((2,6-Difluorophenyl)methyl)-1H-1,2,3-triazole-4-carboxamide Banzel Inovelon |
| Description | Rufinamide(E 2080; CGP 33101; RUF 331) is a new antiepileptic agent that differs structurally from other antiepileptic drugs and is approved as adjunctive therapy for Lennox-Gastaut syndrome (LGS).IC50 Value:Target: in vitro:in vivo: Rufinamide and amitriptyline alleviated injury-induced mechanical allodynia for 4 h (maximal effect: 0.10 ± 0.03 g (mean ± SD) to 1.99 ± 0.26 g for rufinamide and 0.25 ± 0.22 g to 1.92 ± 0.85 g for amitriptyline) in mice [1]. Oral rufinamide suppressed pentylenetetrazol-induced seizures in mice (ED(50) 45.8 mg/kg) but not rats, and was active against MES-induced tonic seizures in mice (ED(50) 23.9 mg/kg) and rats (ED(50) 6.1 mg/kg) [2]. Intraperitoneal rufinamide suppressed pentylenetetrazol-, bicuculline-, and picrotoxin-induced clonus in mice (ED(50) 54.0, 50.5, and 76.3 mg/kg, respectively).Clinical trial: Exploratory Study to Evaluate the Effect of SYN-111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD). Phase 2 |
|---|---|
| Related Catalog | |
| References |
| Density | 1.5±0.1 g/cm3 |
|---|---|
| Boiling Point | 473.8±55.0 °C at 760 mmHg |
| Melting Point | 232-234?C |
| Molecular Formula | C10H8F2N4O |
| Molecular Weight | 238.193 |
| Flash Point | 240.4±31.5 °C |
| Exact Mass | 238.066620 |
| PSA | 73.80000 |
| LogP | 0.05 |
| Vapour Pressure | 0.0±1.2 mmHg at 25°C |
| Index of Refraction | 1.635 |
| Storage condition | −20°C |
| Water Solubility | DMSO: soluble9mg/mL |
| Hazard Codes | F,T |
|---|---|
| Risk Phrases | 11-23/24/25-39/23/24/25-48-41-38-28 |
| Safety Phrases | 7-16-36/37-45-36/37/39-28-26-24/25 |
| RIDADR | UN 1648 3 / PGII |